<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643276</url>
  </required_header>
  <id_info>
    <org_study_id>AIEOP-BFM ALL 2017</org_study_id>
    <nct_id>NCT03643276</nct_id>
  </id_info>
  <brief_title>Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017</brief_title>
  <official_title>International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Schrappe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has&#xD;
      largely changed due to extensive genetic research in recent years: ALL is now considered to&#xD;
      be a very heterogeneous disease group. The leukemia cells present themselves with quite&#xD;
      differently activated regulatory mechanisms of the malignant phenotype. The introduction of&#xD;
      more accurate methods of assessing therapy response (&quot;minimal residual disease [MRD] tests&quot;)&#xD;
      has provided new insights into very different mechanisms of action, including factors&#xD;
      influenced by host factors; this has had practical clinical consequences for the use of more&#xD;
      individualized therapy. Multimodal therapies have enabled a cure level of over 80% for ALL in&#xD;
      this age group. However, the own and international study data show that the therapy toxicity&#xD;
      of the contemporary chemotherapy concepts has become unacceptably high, in particular with&#xD;
      respect to those intensified therapies used for the treatment of patients at high risk of ALL&#xD;
      relapse.&#xD;
&#xD;
      The AIEOP-BFM ALL 2017 study therefore aims for an innovative integrated approach that will&#xD;
      not only adapt the risk stratification to new prognostic markers using more comprehensive&#xD;
      diagnostics, but above all, qualitatively reorient the therapy. The most important&#xD;
      consequence will be that this study is testing immunotherapy with the bispecific antibody&#xD;
      blinatumomab as an alternative to particularly intensive and toxic chemotherapy elements in&#xD;
      precursor B-cell ALL (pB-ALL) patients with detectable chemotherapy resistance and at high&#xD;
      risk of relapse. With the aim to complement the effects of the conventional chemotherapy,&#xD;
      Blinatumomab is in addition tested in the large group of pB-ALL patients at intermediate&#xD;
      relapse risk with seemingly unremarkable leukemia, but who account for a large proportion of&#xD;
      all relapses. Targeted therapy is also used in the form of the proteasome inhibitor&#xD;
      bortezomib for patients with pB-ALL and slow response to the drugs of the induction&#xD;
      chemotherapy with the aim to overcome intrinsic chemotherapy resistance of the ALL cells. In&#xD;
      patients with T-lineage ALL, who have particularly poor chances for cure after relapse, the&#xD;
      established consolidation chemotherapy has proved to be particularly effective. This&#xD;
      chemotherapy phase is therefore tested in a longer and more intensive form in such T-ALL&#xD;
      patients with intermediate or slow early treatment response with the aim to reduce the&#xD;
      relapses rate in this subgroup.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are stratified into 4 early risk groups for therapy during the consolidation phase&#xD;
      (T/early SR, T/early non-SR, pB/early non-HR, pB/early HR) and 5 risk groups for&#xD;
      post-consolidation therapy (T/non-HR, T/HR, pB/SR, pB/MR, pB/HR). Risk stratification is&#xD;
      based on immunophenotypic lineage, genetics of leukemic cells and treatment response on the&#xD;
      basis of cytomorphology and methods for detection minimal residual disease.&#xD;
&#xD;
      The trial includes four randomized study questions testing experimental treatments on top of&#xD;
      the risk-stratified standard chemotherapy backbone:&#xD;
&#xD;
      Primary study questions:&#xD;
&#xD;
      Randomization R-eHR: Early High-risk (early HR) pB-ALL defined by genetics and/or inadequate&#xD;
      treatment response over the course of induction: Can the probability of event-free survival&#xD;
      (pEFS) from time of randomization be improved by additional therapy with the proteasome&#xD;
      inhibitor bortezomib during an extended consolidation treatment phase compared with standard&#xD;
      extended consolidation?&#xD;
&#xD;
      Randomization R-HR: High-risk (HR) pB-ALL defined by genetics and/or inadequate treatment&#xD;
      response by the end of consolidation: Can the pEFS from time of randomization be improved by&#xD;
      a treatment concept including two cycles of post-consolidation immunotherapy with&#xD;
      blinatumomab (15 µg/m²/d for 28 days per cycle) plus 4 doses intrathecal Methotrexate&#xD;
      replacing two conventional highly intensive chemotherapy courses?&#xD;
&#xD;
      Randomization R-MR: Intermediate risk (MR) pB-ALL defined by genetics and intermediate MRD&#xD;
      response: Can the probability of disease-free survival (pDFS) from time of randomization be&#xD;
      improved by additional therapy with one cycle of post-reintensification immunotherapy with&#xD;
      blinatumomab (15 µg/m²/d for 28 days)?&#xD;
&#xD;
      Randomization R-T: Early non-standard risk (early non-SR) T-ALL patients defined by treatment&#xD;
      response over the course of induction: Can the pEFS from time of randomization be improved by&#xD;
      the extension of the standard of care consolidation phase by 14 days with an increase of the&#xD;
      consolidation cumulative doses of Cyclophosphamide, Cytarabine and 6-Mercaptopurine by 50%?&#xD;
&#xD;
      Secondary study questions:&#xD;
&#xD;
      All randomizations: Can the overall survival be improved by the treatment in the experimental&#xD;
      arm?&#xD;
&#xD;
      All randomizations: What is the incidence of treatment-related toxicities and mortality in&#xD;
      the experimental arm compared to the standard arm?&#xD;
&#xD;
      Randomization R-eHR: Can the MRD load after consolidation treatment be reduced by the&#xD;
      additional treatment with bortezomib?&#xD;
&#xD;
      Randomization R-HR: Can treatment-related life-threatening complications and mortality during&#xD;
      the intensified consolidation phase of high-risk treatment be reduced when replacing two&#xD;
      intensive chemotherapy courses by two cycles of immunotherapy with blinatumomab?&#xD;
&#xD;
      Randomization R-HR: What is the proportion of patients with insufficient MRD response to&#xD;
      blinatumomab as defined in the protocol as compared to the MRD response after the HR-2' block&#xD;
      in the control arm?&#xD;
&#xD;
      Randomization R-HR: Can the MRD load after the first treatment cycle (HR 2'/blinatumomab) and&#xD;
      the second cycle (HR-3'/blinatumomab) be reduced in the experimental arm when compared with&#xD;
      conventional intensive chemotherapy? Randomization R-MR: What is the proportion of patients&#xD;
      with positive MRD after reintensification Protocol II who become MRD-negative over the&#xD;
      blinatumomab cycle compared to 4 weeks of standard maintenance therapy?&#xD;
&#xD;
      Randomization R-T: Can the MRD load after consolidation treatment be reduced by extension of&#xD;
      the consolidation phase?&#xD;
&#xD;
      Standard-risk patients: Is the clinical outcome comparable to that obtained for standard-risk&#xD;
      patients in study AIEOP-BFM ALL 2009?&#xD;
&#xD;
      A small subgroup of patients at very high relapse risk is eligible for allogeneic&#xD;
      hematopoietic stem cell transplantation after the intensified consolidation therapy phase.&#xD;
&#xD;
      Patients with T-ALL and hyperleukocytosis (&gt;=100,000/µL) and patients with CNS involvement at&#xD;
      diagnosis (CNS3 status) are eligible for cranial irradiation with 12 Gy if age at time of&#xD;
      irradiation is at least 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">July 14, 2028</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>pB-ALL/MR: 2 parallel groups (R-MR) or 2x2 factorial design (R-eHR, R-MR) depending on early risk group assignment.&#xD;
pB-ALL/HR: 2 parallel groups (R-HR) or 2x2 factorial design (R-eHR, R-HR) depending on early risk group assignment.&#xD;
T-ALL/early non-SR: 2 parallel groups (R-T).&#xD;
pB-ALL/SR: Single group.&#xD;
T-ALL/early SR: Single group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Assessed up to 120 months from start of study</time_frame>
    <description>Randomization R-eHR, R-HR and R-T: Time from randomization until the first event defined as follow: cytomorphological or molecular non-response (resistance to protocol treatment, considered as event at day zero), relapse, second malignancy or death from any cause. This will be called EFS time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Assessed up to 120 months from start of study</time_frame>
    <description>Randomization R-MR: Time from randomization until the first event defined as follow: Relapse, second malignancy or death from any cause. This will be called DFS time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Assessed up to 120 months from start of study</time_frame>
    <description>All patients/randomizations: Time until death from any cause, starting at the same time point as the EFS/DFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>Assessed up to 120 months from start of study</time_frame>
    <description>Frequency and incidence of treatment-related mortality in induction or continuous complete remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events of interest/Serious Adverse Events</measure>
    <time_frame>Assessed up to 120 months from start of study</time_frame>
    <description>Frequency and incidence of adverse events of interest and serious adverse events in specific protocol phases, randomized arms and overall during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD response</measure>
    <time_frame>Measurements of MRD response at end of randomized treatments (intended time frame 13 weeks in R-eHR/R-T, 26 weeks in R-HR, 34 weeks in R-MR).</time_frame>
    <description>MRD load after the randomized treatment phases (R-eHR, R-HR, R-MR and R-T) as well as after the first/second cycle of Blinatumomab or after the HR 2'/HR 3' block (R-HR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Blina Poor-Response</measure>
    <time_frame>Measurements of MRD response intended after 30 weeks from individual start of treatment, assessment of proportion at 120 months from start of study</time_frame>
    <description>Proportion of patients with poor MRD response to the first Blinatumomab cycle (&quot;Blinatumomab Poor-Response&quot;) (R-HR)</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Acute Lymphoblastic Leukemia, Pediatric</condition>
  <arm_group>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction (5 wks): &quot;Protocol IA&quot; with prednisolone, vincristine, daunorubicin, pegaspargase, IT methotrexate (MTX)&#xD;
Consolidation (6 w/4 w): &quot;Consolidation extended&quot; (control arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-mercaptopurine (6-MP), IT MTX, dexamethasone, vincristine, pegaspargase or &quot;Consolidation short&quot; (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX&#xD;
Extra-compartment phase (8 wks): &quot;Protocol M&quot; with 6-MP, HD-MTX, IT MTX&#xD;
Reinduction (6 wks): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine&#xD;
Maintenance (until 2 years after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]&#xD;
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA&quot; with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX&#xD;
Consolidation (6 w): &quot;Consolidation extended+BZM&quot; (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)&#xD;
Extra-compartment phase (8 wks): &quot;Protocol M&quot; with 6-MP, HD-MTX, IT MTX&#xD;
Reinduction (6 wks): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine&#xD;
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]&#xD;
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA&quot; with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX&#xD;
Consolidation (6 w/4 w): &quot;Consolidation extended&quot; (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or &quot;Consolidation short&quot; (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX&#xD;
Extra-compartment phase (8 w): &quot;Protocol M&quot; with 6-MP, HD-MTX, IT MTX&#xD;
Reinduction (6 w): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine&#xD;
Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)&#xD;
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX&#xD;
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA&quot; with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX&#xD;
Consolidation (6 w): &quot;Consolidation extended+BZM&quot; (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)&#xD;
Extra-compartment phase (8 w): &quot;Protocol M&quot; with 6-MP, HD-MTX,IT MTX&#xD;
Reinduction (6 weeks): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, PEG-L-asparaginase, IT MTX, cyclophosphamide, tioguanine, cytarabine&#xD;
Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)&#xD;
Maintenance phase (until 2 yrs after initial diagnosis): 6-MP, MTX&#xD;
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction (5 w): as in other pB arms&#xD;
Consolidation (6 w/4 w): &quot;Consolidation extended&quot; (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT methotrexate, dexamethasone, vincristine, pegaspargase or &quot;Consolidation short&quot; (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX&#xD;
Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide&#xD;
Reinduction (3x4 w): &quot;Protocol III&quot; given 3 times with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine&#xD;
Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX&#xD;
Erwinase is given in case pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): as in other pB arms&#xD;
Consolidation (6 w): &quot;Consolidation extended+BZM&quot; (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)&#xD;
Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide&#xD;
Reinduction (3x4 w): as in arm &quot;pB: early (non-)HR-standard/HR-standard&quot;&#xD;
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX&#xD;
Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): as in other pB arms&#xD;
Consolidation (6 w/4 w): &quot;Consolidation extended&quot; (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or &quot;Consolidation short&quot; (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX&#xD;
Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)&#xD;
Reinduction (3x4 weeks): as in arm &quot;pB: early (non-)HR-standard/HR-standard&quot;&#xD;
Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX&#xD;
Erwinase is given in case of pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): as in other pB arms&#xD;
Consolidation (6 w): &quot;Consolidation extended+BZM&quot; (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)&#xD;
Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)&#xD;
Reinduction (3x4 weeks): as in arm &quot;pB: early (non-)HR-standard/HR-standard&quot; Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX&#xD;
Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA&quot; with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX&#xD;
Consolidation (4 w): &quot;Consolidation short&quot; with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX&#xD;
Extra-compartment phase (8 w): &quot;Protocol M&quot; with 6-MP, HD-MTX, IT MTX&#xD;
Reinduction (6 w): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine&#xD;
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX&#xD;
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA-Dexa&quot; with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or &quot;Protocol IA-CPM&quot; with prednisolone instead of dexamethasone and additional CPM&#xD;
Consolidation (4 w): &quot;Protocol IB regular&quot; (control arm in randomization. R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX&#xD;
non-HR extra-compartment phase and reinduction: as in arm &quot;pB: early non-HR/SR&quot;&#xD;
HR intensified consolidation and reinduction: as in arm &quot;pB: early (non-)HR-standard/HR-standard&quot;&#xD;
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX&#xD;
Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA-Dexa&quot; with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or &quot;Protocol IA-CPM&quot; with prednisolone instead of dexamethasone and additional CPM&#xD;
Consolidation (6 w): &quot;Protocol IB long&quot; (experimental arm in randomization R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX&#xD;
non-HR extra-compartment phase and reinduction: as in arm &quot;pB: early non-HR/SR&quot;&#xD;
HR intensified consolidation and reinduction: as in arm &quot;pB: early (non-)HR-standard/HR-standard&quot;&#xD;
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX&#xD;
Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Induction (5 w): &quot;Protocol IA-Dexa&quot; with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX&#xD;
Consolidation (4 w): &quot;Protocol IB regular&quot; with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX&#xD;
Extra-compartment phase (8 w): &quot;Protocol M&quot; with 6-MP, HD-MTX, IT MTX&#xD;
Reinduction (6 w): &quot;Protocol II&quot; with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine&#xD;
Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX&#xD;
Erwinase is given in case of allergy to pegaspargase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Experimental therapy in randomizations R-HR and R-MR</description>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Experimental therapy in randomization R-eHR</description>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myocet</intervention_name>
    <description>Part of intensification block Myocet-FLA for patients with very high relapse risk</description>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Part of intensification block Myocet-FLA for patients with very high relapse risk</description>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-Mercaptopurine</intervention_name>
    <description>Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tioguanin</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vindesine</intervention_name>
    <description>Part of standard chemotherapy</description>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erwinase</intervention_name>
    <description>Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction</description>
    <arm_group_label>T: early SR/non-HR</arm_group_label>
    <arm_group_label>T: early non-SR-exp/(non-)HR</arm_group_label>
    <arm_group_label>T: early non-SR-standard/(non-)HR</arm_group_label>
    <arm_group_label>pB: early (non)HR-standard/MR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-exp.</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/HR-standard</arm_group_label>
    <arm_group_label>pB: early (non-)HR-standard/MR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./HR-standard</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-exp.</arm_group_label>
    <arm_group_label>pB: early HR-exp./MR-standard</arm_group_label>
    <arm_group_label>pB: early non-HR/SR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  newly diagnosed acute lymphoblastic leukemia or&#xD;
&#xD;
          -  newly diagnosed mixed phenotype acute leukemia (MPAL) meeting one of the following&#xD;
             criteria:&#xD;
&#xD;
          -  biphenotypic with a dominant T or B lineage assignment&#xD;
&#xD;
          -  bilineal either with a dominant lymphoblastic population or if another reasonable&#xD;
             rationale exists to treat the patient with an ALL-based therapy regimen&#xD;
&#xD;
          -  newly diagnosed acute undifferentiated leukemia&#xD;
&#xD;
          -  age &lt; 18 years (up to 17 years and 365 days) at the day of diagnosis&#xD;
&#xD;
          -  patient enrolled in a participating center&#xD;
&#xD;
          -  written informed consent to trial participation and transfer and processing of data A&#xD;
             subsequent removal from the study is only allowed if the inclusion criteria turn out&#xD;
             not to be fulfilled or in the case of pregnancy of the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ph+ (BCR-ABL1 or t(9;22)-positive) ALL&#xD;
&#xD;
          -  bilineal leukemia with a lymphoblastic and a separate non-lymphoblastic (≥ 10% of&#xD;
             total cells) blast subset&#xD;
&#xD;
          -  pre-treatment with cytostatic drugs&#xD;
&#xD;
          -  glucocorticoid pre-treatment with ≥ 1 mg/kg/d for more than two weeks during the last&#xD;
             month before diagnosis&#xD;
&#xD;
          -  treatment started according to another protocol&#xD;
&#xD;
          -  underlying disease that does not allow treatment according to the protocol (e.g.&#xD;
             severe congenital heart disease, Charcot-Marie Syndrome, Ataxia-teleangiectasia…)&#xD;
&#xD;
          -  ALL diagnosed as second malignancy and preceding chemotherapy and/or radiotherapy&#xD;
&#xD;
          -  evidence of pregnancy or lactation period&#xD;
&#xD;
          -  Sexually active adolescents not willing to use highly effective contraceptive method&#xD;
             (pearl index &lt;1) until 12 months after end of anti-leukemic therapy&#xD;
&#xD;
          -  participation in another clinical trial except for add-on trials within the scope of&#xD;
             supportive care approved by the sponsor&#xD;
&#xD;
          -  live vaccine immunization within 2 weeks before start of protocol treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schrappe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, University Hospital of Schleswig-Holstein, Campus Kiel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Möricke, MD</last_name>
    <phone>+4943150020150</phone>
    <email>a.moericke@pediatrics.uni-kiel.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lile Bauer</last_name>
    <phone>+4943150020152</phone>
    <email>lile.bauer@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Draga Barbaric</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano Dalla-Pozza</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ.Klinik für Kinder- und Jugendheilkunde Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Benesch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Meister</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Ebetsberger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LKH Salzburg</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Jones</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Anna Kinderspital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andishe Attarbaschi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaroslav Štěrba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiří Hak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Pospíšilová</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava-Poruba</name>
      <address>
        <city>Ostrava-Poruba</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomáš Kuhn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Plzeň</name>
      <address>
        <city>Plzeň</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomáš Votava</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Starý</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masaryk´s Hospital Ústí nad Labem</name>
      <address>
        <city>Ústí nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Procházková</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Hospital České Budějovice</name>
      <address>
        <city>České Budějovice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Timr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderklinik der med. Fakultät der RWTH, Bereich Hämatologie/Onkologie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udo Kontny</last_name>
      <phone>+49 241808</phone>
      <phone_ext>9902</phone_ext>
      <email>ukontny@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>I. Klinik für Kinder u. Jugendliche, Klinikum Augsburg, Hämatologie/ Onkologie</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Frühwald</last_name>
      <phone>+49 821400</phone>
      <phone_ext>3631</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lothar Schweigerer</last_name>
      <phone>+49 309401</phone>
      <phone_ext>2367</phone_ext>
      <email>lschweigerer@berlin.helio-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderklinik der Charité, Campus Virchow Klinikum (CVK), Abt.: Kinderhämatologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arend Stackelberg</last_name>
      <phone>+49 30450566</phone>
      <phone_ext>833</phone_ext>
      <email>arend.stackelberg@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Krankenhaus, Kinderklinik</name>
      <address>
        <city>Braunschweig</city>
        <zip>38118</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Eberl</last_name>
      <phone>+49 531595</phone>
      <phone_ext>1424</phone_ext>
      <email>w.eberl@klinkum-braunschweig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH, Klinik für Kinder- und Jugendmedizin, Hämatologie / Onkologie</name>
      <address>
        <city>Chemnitz</city>
        <zip>09009</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Hofmann</last_name>
      <phone>+49 3713332</phone>
      <phone_ext>4287</phone_ext>
      <email>a.hofmann@skc.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum, Kinderklinik, Abt. Hämatologie/Onkologie</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Schwabe</last_name>
      <phone>+49 35546</phone>
      <phone_ext>2332</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vestische Kinder- u. Jugendklinik, Universitätsklinik Witten/Herdecke</name>
      <address>
        <city>Datteln</city>
        <zip>45711</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wiesel</last_name>
      <phone>+49 236397</phone>
      <phone_ext>5846</phone_ext>
      <email>th.wiesel@kinderklinik-datteln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund, Klinik f. Kinder- und Jugendmedizin</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Schneider</last_name>
      <phone>+49 2319532</phone>
      <phone_ext>1050</phone_ext>
      <email>dominik.schneider@klinikumdo.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Knöfler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arndt Borkhardt, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt GmbH, Klinik für Kinderheilkunde</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Sauerbrey</last_name>
      <phone>+49 36178</phone>
      <phone_ext>4501</phone_ext>
      <email>axel.sauerbrey@helios-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Metzler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Beier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Klingebiel, MD</last_name>
      <phone>49-69-6301-5094</phone>
      <email>thomas.klingebiel@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetskinderklinik - Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Niemeyer, MD</last_name>
      <phone>49-761-270-4506</phone>
      <email>charlotte.niemeyer@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Justus-Liebig-Universität, Zentrum für Kinderheilkunde, Abt. Hämatologie/Onkologie</name>
      <address>
        <city>Gießen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Mauz-Körholz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Kinder und Jugendmedizin, Allgemeine Pädiatrie mit Poliklinik/Pädiatrische Onkologie und Hämatologie</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Lode</last_name>
      <phone>+49 383486</phone>
      <phone_ext>6325</phone_ext>
      <email>holger.lode@uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik Päd. I, Hämatologie/Onkologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Kühnle</last_name>
      <phone>+49 55139</phone>
      <phone_ext>6201</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Zentrum Kinderheilkunde u. Jugendmedizin</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christin Linderkamp</last_name>
      <phone>+49 511532</phone>
      <phone_ext>6710</phone_ext>
      <email>linderkamp.christin@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik, Päd. Onkologie, Hämatologie, und Immunologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Behnisch</last_name>
      <phone>+49 622156</phone>
      <phone_ext>4555</phone_ext>
      <email>wolfgang.behnisch@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Heilbronn GmbH, Klinik für Kinderheilkunde und Jugendmedizin/Perinatalzentrum</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermann Full</last_name>
      <phone>+49 713149</phone>
      <phone_ext>3702</phone_ext>
      <email>hermann.full@slk-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftskrankenhaus Herdecke, Kinderabteilung</name>
      <address>
        <city>Herdecke</city>
        <zip>58313</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Längler</last_name>
      <phone>+49 233062</phone>
      <phone_ext>3893</phone_ext>
      <email>a.laengler@gemeinschaftskrankenhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Graf</last_name>
      <phone>49-6841-168-8397</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum, der Friedrich-Schiller-Universität, Klinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Jena</city>
        <zip>7740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Gruhn</last_name>
      <phone>+49 364193</phone>
      <phone_ext>8220</phone_ext>
      <email>bernd.gruhn@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. Leipold</last_name>
      <phone>49-721-9740</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>D-34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Nathrath, MD</last_name>
      <phone>49-561-980-3382</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Allgemeine Paediatrie, Univ.-Klinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schrappe</last_name>
      <phone>+49 431597</phone>
      <phone_ext>1620</phone_ext>
      <email>m.schrappe@pediatrics.uni-kiel.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln GmbH, Kinderkrankenhaus Riehl</name>
      <address>
        <city>Köln</city>
        <zip>50735</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aram Prokop</last_name>
      <phone>+49 2218907</phone>
      <phone_ext>5158</phone_ext>
      <email>prokopa@klinken-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med. Einrichtungen der Universität zu Köln, Klinik für Allg. Kinderheilkunde, Onkologisch-hämatologische Station</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Simon</last_name>
      <phone>+49 221478</phone>
      <phone_ext>4380</phone_ext>
      <email>thorsten.simon@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department für Frauen- und Kindermedizin, Abteilung für Pädiatrische Onkologie, Hämatologie und Hämostaseologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Fischer</last_name>
      <phone>0341-97 26</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universität zu Lübeck, Klinik für Kinder- u. Jugendmedizin, Abt. Hämatologie/ Onkologie/Immunologie</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melchior Lauten</last_name>
      <phone>+49 451500</phone>
      <phone_ext>2557</phone_ext>
      <email>lauten@paedia.ukl.mu-luebeck.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg, Klinik für Päd. Hämatologie/Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Vorwerk</last_name>
      <phone>+49 391671</phone>
      <phone_ext>7210</phone_ext>
      <email>peter.vorwerk@med.ovgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim gGmbH, Kinderklinik, Abt. Hämatologie/Onkologie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Dürken</last_name>
      <phone>+49 621383</phone>
      <phone_ext>2244</phone_ext>
      <email>matthias.duerken@kikli.ma.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Dürken, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Erdlenbruch</last_name>
      <phone>+49 571</phone>
      <phone_ext>8010</phone_ext>
      <email>bernhard.erdlenbruch@klinikum-minden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städt. Krankenhaus München GmbH, Krankenhaus München-Schwabingen, Kinderklinik d. TU</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Wawer</last_name>
      <phone>+49 893068</phone>
      <phone_ext>2261</phone_ext>
      <email>angela.wawer@lrz.tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilian-Universität, Dr. von Haunersches Kinderspital</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Feuchtinger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik, Päd. Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Rössig</last_name>
      <phone>+49 251834</phone>
      <phone_ext>5644</phone_ext>
      <email>rossig@ukmuenster.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cnopf'sche Kinderklinik, Onkologie</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Scheurlen</last_name>
      <phone>+49 91133</phone>
      <phone_ext>40323</phone_ext>
      <email>wolfram.scheurlen@diakonieneudettelsau.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH, Zentrum für Kinder- u. Jugendmedizin, (Elisabeth Kinderkrankenhaus)</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermann Müller</last_name>
      <phone>+49 441403</phone>
      <phone_ext>2013</phone_ext>
      <email>mueller.hermann@klinikum-oldenburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selim Corbacioglu, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl-Friedrich Classen</last_name>
      <phone>+49 381494</phone>
      <phone_ext>7000</phone_ext>
      <email>carl-friedrich.classen@med.uni-rostock.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios-Klinik, Sankt Augustin GmbH</name>
      <address>
        <city>Sankt Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Reinhard</last_name>
      <phone>+49 224124</phone>
      <phone_ext>9304</phone_ext>
      <email>h.reinhard@asklepios.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken Schwerin, Klinik f. Kinder-u. Jugendmedizin</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Güttel</last_name>
      <phone>+49 385520</phone>
      <phone_ext>2710</phone_ext>
      <email>christian.guettel@helios-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Olga-Hospital, Kinderklinik, Pädiatrisches Zentrum, Abt. Hämatologie/Onkologie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Bielack</last_name>
      <phone>+49 711992</phone>
      <phone_ext>2461</phone_ext>
      <email>st.bielack@olgahospital.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Trier, Mutterhaus der Borromaeerinnen, Pädiatrische Abteilung</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Weis</last_name>
      <phone>+49 651947</phone>
      <phone_ext>2654</phone_ext>
      <email>weis@mutterhaus.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Ebinger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus M. Debatin, MD</last_name>
      <phone>49-731-5000</phone>
      <email>klaus-michael.debatin@medizin.uni-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stadtkrankenhaus, Kinderklinik</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Mukodzi</last_name>
      <phone>+49 5361</phone>
      <phone_ext>8000</phone_ext>
      <email>sally.mukidzi@klinikum-wolfsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaets - Kinderklinik Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. G. Schlegel, MD</last_name>
      <phone>49-931-2012-7856</phone>
      <email>schlegel@mail.uni-wuerzburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Kapelushnik</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nira Arad-Cohen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gal Goldstein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schneider Children Medical Center of Israel</name>
      <address>
        <city>Petach-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gil Gilad</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center Tel-Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bella Bielorai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana children hospital</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronit Elhasid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedali riuniti</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Pierani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOUC Policlinico Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Santoro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Provenzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Pession</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fulvio Porta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Maria Mura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliero universitaria</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Lo Nigro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Consarino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.O. Annunziata - A. O. Cosenza</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenico Sperlì</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Meyer</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tommaso Casini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concetta Micalizzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico di Modena Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Cellini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica pediatrica Fondazione MBBM</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Biondi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Rossi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AORN Santobono Pausilipon</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosanna Parasole</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Caterina Putti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civico ARNAS Civico e Di Cristina</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ottavio Ziino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliero-universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelica Barone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Zecca</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Maria della misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Caniglia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Onofrillo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara Pisa</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuela De Marco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grande ospedale metropolitano B-M-M</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Ronco</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale infermi</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Pericoli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Ruggiero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I Università Sapienza di Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Foà</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Casa sollievo della sofferenza&quot;</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saverio Ladogana</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O.U. Città della salute e della scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Kiren</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Cesaro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinika pediatrickej hematológie a onkológie SZU a DFNsP</name>
      <address>
        <city>Banská Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Bubanská</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comenius University Children's Hospital</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Kolenova</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Detská fakultná nemocnica Košice</name>
      <address>
        <city>Košice</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natália Galóová</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Scheinemann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspital beider Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas von der Weid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bellinzona</name>
      <address>
        <city>Bellinzona</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierluigi Brazzola</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Rössler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HUG Hôpitaux Universitaires de Gèneve</name>
      <address>
        <city>Genève</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Baleydier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUV Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Ceppi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital-Kinderspital Luzern</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freimut Schilling</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ostschweizer Kinderspital</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Greiner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Niggli</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Martin Schrappe</investigator_full_name>
    <investigator_title>Professor MD, FRCP (Glasg), Chair of Pediatrics I</investigator_title>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Childhood</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Blinatumomab</keyword>
  <keyword>Proteasome Inhibitor</keyword>
  <keyword>Bispecific antibody</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Blinatumomab</mesh_term>
    <mesh_term>Vindesine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

